ReviewThe Journal of infectious diseases2020
Preventing Infection by Human Cytomegalovirus.
Review in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- First evidence of clinical protection from an EEHV1A mRNA vaccine in naturally infected juvenile elephants.Journal of virology · 2026Article
- Evaluation of a multiantigen mRNA vaccine against EEHV1A in Asian elephants.Journal of virology · 2026Article
- Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026Review
- Review
- A vaccine against cytomegalovirus: how close are we?The Journal of clinical investigation · 2025Article
- Spatial kinetics and immune control of murine cytomegalovirus infection in the salivary glands.PLoS computational biology · 2024Article
- Article
- Updates in Cytomegalovirus Prevention and Treatment in Solid Organ Transplantation.Infectious disease clinics of North America · 2023Review
- Targeted Protein-Specific Multi-Epitope-Based Vaccine Designing against Human Cytomegalovirus by Using Immunoinformatics Approaches.Vaccines · 2023Article
- Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development.Annual review of virology · 2022Review
- An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine.Vaccines · 2022Article
- Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice.PloS one · 2022Article
- Understanding the interaction between cytomegalovirus and tuberculosis in children: The way forward.PLoS pathogens · 2021Review
- Evasion of the Host Immune Response by Betaherpesviruses.International journal of molecular sciences · 2021Review
- Review
- Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The way to a successful vaccine against human cytomegalovirus is hampered by the peculiar biology of this infection. However, some candidate vaccines have been shown to protect seronegative women and transplant recipients, and we should know soon whether they can prevent congenital infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.